This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Maruho Co., Ltd.
Drug Names(s): MBI 594AN, MX-594AN, omiganan 2.5%
Description: Omiganan is a novel, topical cationic, antimicrobial peptide. Its mechanism of action non-specifically interferes with the cell membrane, making it both bactericidal and fungicidal. The compound has not induced any significant resistance after resistance testing.
Migenix and Cutanea Life Sciences
In December 2005, Migenix and Cutanea Life Sciences entered into a License Agreement to develop and commercialize Omiganan for a number of dermatological indications. Migenix will receive a small up-front payment and up to approximately US$21 million in development and commercialization milestone payments, as wellas royalties on net sales. Under the terms of the agreement, Cutanea will have exclusive worldwide rights to develop and market Omiganan and its analogues. Cutanea will take fullresponsibility for funding all development activities including all formulation, clinical, regulatory, and commercialization costs.
In February 2010, Migenix announced that it entered into an investment agreement in respect of a plan of arrangement with Madison Pacific Properties to reorganize Migenix and provide it with non-dilutive funding in the amount of $4,000,000. Under the terms of the Investment Agreement, Madison made an investment in Migenix in...See full deal structure in Biomedtracker
Partners: BioWest Therapeutics, Inc.
Pink Sheet FDA's ANDA Approvals
Additional information available to subscribers only: